1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Sugentech, Inc.

Sugentech, Inc.

KKRX:253840
4,190.00
KRW
+50.00
(+1.21%)
-1,514.82EPS
58.41BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
376.4
773.33
311.27
2,958.86
5,022.66
6,398.98
450.99
660.61
615.96
640.17
Basic EPS, GAAP
-2,293.5
-5,807
-774
-2,935
2,352
1,686
-1,090
-994
-1,525
-1,505.18
Free Cash Flow per Basic Share
-122.65
-722.44
-483.82
725.11
2,191.55
910.43
-1,136.93
-619.48
-983.71
-1,045.08
Dividend per Share
- -
- -
- -
- -
- -
- -
157.07
- -
- -
- -
Book Value per Share
-6,699.09
1,352.73
1,880.41
4,125.87
6,514.04
8,640.89
7,360.95
6,352.42
4,990.97
4,468.64
Tangible Book Value per Share
-6,723.8
1,339.55
1,863.8
4,111.02
6,498.48
8,620.48
7,317.36
6,268.86
4,942.46
4,400.59
Basic Weighted Avg Shares
9
7
12
14
15
16
16
15
15
15
Sales/Revenue/Turnover
3,440
5,449
3,845
41,352
77,201
101,399
7,132
10,097
9,417
9,784
Operating Margin (%)
-92.31
-84.48
-183.85
54.44
45.09
24.63
-319.08
-218.1
-199.86
-192.84
Depreciation Expense
534
514
625
883
1,395
3,617
4,783
4,855
3,241
1,878
Net Income, GAAP
-20,960
-40,915
-9,561
-41,018
36,152
26,717
-17,238
-15,193
-23,314
-23,005
Effective Tax Rate (%)
- -
- -
- -
- -
16.53
17.46
- -
- -
- -
- -
Profit Margin (%)
-609.32
-750.91
-248.66
-99.19
46.83
26.35
-241.69
-150.47
-247.58
-235.12
Working Capital
-2,762
9,092
16,757
45,686
80,742
92,742
59,418
56,367
50,641
35,297
LT Debt
12,975
1,800
1,129
913
670
1,123
492
133
13,494
13,925
Total Equity
-32,811
15,456
24,320
63,143
100,745
140,577
112,455
97,295
76,544
68,560
Return on Invested Capital (%)
- -
- -
- -
- -
30.26
14.33
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
40.74
20.78
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-48.09
-93.85
44.14
22.15
-13.63
-14.5
-26.89
-29.28

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
967
934
895
LT Borrowings
10,383
10,691
11,001
LT Finance Leases
3,111
3,022
2,924
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
93,879
70,562
58,407

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
55,890
51,326
39,649
Cash, Cash Equivalents & STI
44,663
40,516
28,732
Accounts Receivable, Net
1,816
2,021
1,725
Inventories
6,990
6,228
5,151
Total Current Liabilities
5,250
4,743
4,352
Payables & Accruals
- -
- -
- -
ST Debt
967
934
895
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.86%
-21.33%
Free Cash Flow
- -
-7.58%
58.83%
Net Income, GAAP
- -
-67.43%
53.46%
Sales/Revenue/Turnover
- -
11.98%
-6.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,960
1,557
4,113
2,467
10,097
2025
1,889
3,173
1,483
2,872
9,417
2026
2,346
3,084
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-258
116
-284
-567.09
-994
2025
-203
-343
-246.93
-731.17
-1,525
2026
-278.88
-248
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mi-Jin Sohn
Full Time Employees
153
Sector
Health technology
Industry
Medical specialties
Address
187, Techno 2-ro Daejeon DE South Korea 34028
IPO Date
Nov 11, 2016
Website
sugentech.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Sugentech Inc. (253840.KQ) develops, manufactures and sells in-vitro diagnostic systems and reagents based on biotechnology, nanotechnology and information technology, with core offerings spanning multiplex immunoblot systems for allergy, food intolerance and autoimmune disease testing; point-of-care testing (POCT) products including the SGTi-flex line of rapid antigen tests for infectious diseases such as COVID-19, influenza and dengue, the INCLIX line of quantitative analyzers for diabetes, cardiovascular markers, hormones and D-dimer; digital healthcare and home-testing solutions under the Surearly SMART brand that monitor female hormones (hCG, LH, P3G and others) via app-connected devices for pregnancy, ovulation and menopause tracking; folic acid supplements under the SOLGAR brand; and molecular diagnostic reagents alongside therapeutic drug monitoring services. Founded in 2011 and headquartered in Daejeon, South Korea, the company operates primarily in the medical equipment and diagnostics sector, serving hospitals, clinics, laboratories and consumers with products distributed domestically and internationally across more than 100 countries including Indonesia, Russia, Canada, Brazil, Germany, the UK and others. Recent developments include headquarters relocation to a new facility in Yuseong-gu, Daejeon; establishment of a corporate venture capital arm and Sejong Campus PIUM research site; receipt of approximately KRW 12.5 billion in funding from Synergy IB Investment and related entities; regulatory approvals for expanded product lines such as SGTi-flex COVID-19 & Flu A/B Ag Combo/DUO, food intolerance tests, type 1 diabetes kits and Surearly Smart Ovulation tests by Korea MFDS, FDA, CE-IVDR and agencies in Russia, Canada and Brazil; achievement of MDSAP certification, renewal of Innovative Leading Medical Device status and Export USD 50 Million Tower Award; and revenue growth to 10.10 billion KRW in 2024 reflecting 41.57% year-over-year increase driven by POCT and digital diagnostics demand.